ClinicalTrials.gg
CompletedNCT03355560Updated May 6, 2026Results posted

Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

A Phase 2 interventional study of Nivolumab in Head and Neck Cancer, sponsored by Trisha Wise-Draper. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Trisha Wise-Draper · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing nivolumab in Head and Neck Neoplasms — 1 open to participants now, 6 under way, 1 of them phase 3. Nivolumab · Head and Neck Neoplasms.

Enrollment
6th of 18
39 · median 24
Started
2017
with 3 others
Phase 2
10 of 18
none open now
Registered
8th of 18
by date

Among the 18 studies testing nivolumab in Head and Neck Neoplasms, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 8th registered.

Head and Neck Neoplasms

2,716 studies on the registry are indexed under Head and Neck Neoplasms; 598 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 18 studies testing nivolumab in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing nivolumab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.

03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior definitive therapy with radiation (with or without prior surgical resection and/or chemotherapy) who have underwent salvage resection with curative intent and have no other curable options
  • Pre-operative scans including chest imaging preferably PET/CT and CT neck w/contrast. MRI neck is acceptable if contrast .
  • Able to provide archived or resected tissue.
  • Adequate performance status and labs.

Exclusion criteria

Exclusion Criteria:

  • Patients who did not receive at least radiotherapy as prior definitive treatment.
  • Patients who have gross measurable residual disease after surgery or those who underwent surgery for palliative purposes i.e. for symptom control.
  • Has nasopharyngeal or sinonasal carcinoma.
  • Has confirmed disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Nivolumab

    Nivolumab starting 4-11 weeks after surgery for 6 doses.

    Drug: Nivolumab

Interventions

  • Nivolumab 480 mg IV infusion

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab

    As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one Grade 3 or Grade 4 adverse while on treatment of nivolumab.

    Time frame: AEs were collected during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.

Secondary outcomes

  1. Percentage of Patients With Any Grade Adverse Events of During Treatment of Nivolumab

    As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one adverse while on treatment of nivolumab for a minimum of 30 days following the last dose of study treatment. Adverse Events were not collected beyond the 30 days following the last dose.

    Time frame: AE collection occurs during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.

  2. Disease Free Survival

    The primary endpoint of this study was disease free survival (DFS) at 2-years as measured from the time of treatment allocation to the first evidence of any tumor or death from any cause. The "median follow-up of 22.1 months" reflects the actual duration of follow-up across participants at the time of data analysis. While the outcome measure was designed to be assessed at the 2-year mark, not all participants had reached exactly 24 months of follow-up when the data were analyzed. Therefore, the median follow-up time represents the central tendency of the follow-up duration for the cohort.

    Time frame: Median follow up was 22.1 months

  3. Disease Free Survival

    Time frame: 2 year

07

Results

Posted May 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneNivolumab
Started39
Completed39
Not completed0

Outcome measures

PrimaryPercentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab

As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one Grade 3 or Grade 4 adverse while on treatment of nivolumab.

Time frame:
AEs were collected during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.
Reported as:
Count of participants · Participants
Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab
ParticipantsNivolumab
Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab17
SecondaryPercentage of Patients With Any Grade Adverse Events of During Treatment of Nivolumab

As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one adverse while on treatment of nivolumab for a minimum of 30 days following the last dose of study treatment. Adverse Events were not collected beyond the 30 days following the last dose.

Time frame:
AE collection occurs during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.
Reported as:
Count of participants · Participants
Percentage of Patients With Any Grade Adverse Events of During Treatment of Nivolumab
ParticipantsNivolumab
Percentage of Patients With Any Grade Adverse Events of During Treatment of Nivolumab37
SecondaryDisease Free Survival

The primary endpoint of this study was disease free survival (DFS) at 2-years as measured from the time of treatment allocation to the first evidence of any tumor or death from any cause. The "median follow-up of 22.1 months" reflects the actual duration of follow-up across participants at the time of data analysis. While the outcome measure was designed to be assessed at the 2-year mark, not all participants had reached exactly 24 months of follow-up when the data were analyzed. Therefore, the median follow-up time represents the central tendency of the follow-up duration for the cohort.

Time frame:
Median follow up was 22.1 months
Reported as:
Number · percentage of participants
Disease Free Survival
percentage of participantsNivolumab
Disease Free Survival71.4 (57.8 to 88.1)
SecondaryDisease Free Survival
Time frame:
2 year
Reported as:
Number · Percentage of subjects
Disease Free Survival
Percentage of subjectsNivolumab
Disease Free Survival71.37 (57.8 to 88.8)

Adverse events

Collected over AEs were collected during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab10/39 (25.6%)9/39 (23.1%)37/39 (94.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventNivolumab
Respiratory failureRespiratory, thoracic and mediastinal disorders2/39
Abdominal wall cellulitisInfections and infestations1/39
Acute kidney injuryRenal and urinary disorders1/39
AspirationRespiratory, thoracic and mediastinal disorders1/39
Bone infectionInfections and infestations1/39
Cardiac arrestCardiac disorders1/39
EncephalopathyNervous system disorders1/39
HypotensionVascular disorders1/39
Malignant Neoplasm ProgressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/39
Peripheral sensory neuropathyNervous system disorders1/39
Most frequent other events
Showing 10 of 155
Most frequent other events
EventNivolumab
FatigueGeneral disorders14/39
Weight lossInvestigations9/39
CoughRespiratory, thoracic and mediastinal disorders7/39
DiarrheaGastrointestinal disorders7/39
Weight gainInvestigations7/39
AnorexiaMetabolism and nutrition disorders6/39
DysphagiaGastrointestinal disorders6/39
DyspneaRespiratory, thoracic and mediastinal disorders6/39
PainGeneral disorders6/39
ParesthesiaNervous system disorders6/39

Baseline characteristics

39 subjects that received at least one dose of Nivolumab

Age, Continuous
Age, Continuous(years)Nivolumab
Median68 (49 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab
Female12
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nivolumab
Hispanic or Latino0
Not Hispanic or Latino39
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American3
White34
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Nivolumab
United States39
>10 pack year tobacco smoking history
>10 pack year tobacco smoking history(Participants)Nivolumab
Count of participants24
08

Study locations

2 sites
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • UC Health
    Cincinnati, Ohio 45219, United States
09

References and documents

Publications

  • Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, Kurtzweil N, Riaz MK, Takiar V, Nagasaka M, Patil Y, Zender C, Tang A, Cervenka B, McGrath J, Korn WM, Hinrichs BH, Jandarov R, Harun N, Sukari A, Wise-Draper TM. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Aug 15;28(16):3464-3472. doi: 10.1158/1078-0432.CCR-21-4554. PubMed 35653116 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jan 2024, 72 months.

Results were first posted in May 2026, 2 years 4 months after primary completion.

Of 216 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's 72 months is above that.

Counting every sponsor, half of 260 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2017
First posted
Nov 28, 2017
StartActual
Dec 6, 2017
Primary completionActual
Jan 1, 2024
CompletionActual
Apr 15, 2026
Results first posted
May 6, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03355560
Lead sponsor
Trisha Wise-Draper
Responsible party
Trisha Wise-Draper (Principal Investigator, University of Cincinnati) — Sponsor-investigator
First posted
Nov 28, 2017
Start date
Dec 6, 2017
Primary completion
Jan 1, 2024
Completion
Apr 15, 2026
Results posted
May 6, 2026
Last update
May 6, 2026

Study contacts

Trisha Wise-Draper, MD
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion